|
Pembrolizumab (KEYTRUDA® ) Clinical Trials
16 actively recruiting trials across 13 locations
No change since August 2026
Also known as: KEYTRUDA®, Keytruda, Pembrolizumab
Pipeline
Phase 1: 1Phase 2: 4Phase 3: 1Phase 1/2: 7Phase 2/3: 3
Top Sponsors
- Eikon Therapeutics3
- Bicara Therapeutics2
- VLP Therapeutics1
- Synthekine1
- National Cancer Institute (NCI)1
Indications
- Cancer16
- Lung Cancer5
- Advanced Solid Tumor3
- Breast Cancer3
- Recurrent Head and Neck Squamous Cell Carcinoma2
Other3 trials
Birmingham, Alabama1 trial
Daphne, Alabama1 trial
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Southern Cancer Center, P.C.
Phase 2/3
Dothan, Alabama1 trial
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
XCancer Research Network/Dothan Hematology & Oncology
Phase 1/2
Chandler, Arizona1 trial
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Ironwood Cancer & Research Centers
Phase 2/3
Scottsdale, Arizona1 trial
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Honor Health Research Institute
Phase 1/2
Tucson, Arizona1 trial
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
University of Arizona Cancer Center
Phase 1/2
San Diego, California1 trial
A Beta-only IL-2 ImmunoTherapY Study
Sharp Memorial Hospital
Phase 1/2
Stanford, California1 trial
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Stanford University
Phase 1
New Haven, Connecticut1 trial
Bethesda, Maryland1 trial
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center
Phase 2
Morristown, New Jersey1 trial
New York, New York1 trial
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Tisch Cancer Institute (TCI), Icahn School of Medicine
Phase 1/2
Tyler, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.